- Report
- November 2023
- 109 Pages
Global
From €3500EUR$3,904USD£3,119GBP
- Drug Pipelines
- March 2021
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- July 2020
- 80 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- May 2022
- 41 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- October 2021
- 296 Pages
Global
From €3565EUR$3,712USD£3,069GBP
- Report
- February 2024
- 180 Pages
Global
From €5282EUR$5,499USD£4,547GBP
The Urinary Incontinence Drug market is a subset of the Urological Disorders Drugs market, which includes drugs used to treat a variety of conditions related to the urinary system. Urinary Incontinence Drugs are used to treat the involuntary leakage of urine, which can be caused by a variety of conditions, including overactive bladder, stress incontinence, and urge incontinence. These drugs can be administered orally, topically, or through injections. Commonly used drugs include anticholinergics, beta-3 agonists, and alpha-blockers.
Some of the companies in the Urinary Incontinence Drug market include Allergan, Astellas Pharma, Pfizer, Merck, and Sanofi. Show Less Read more